Currently available biomarkers for Alzheimer’s disease are of limited availability due to high costs and perceived invasiveness. New studies reveal that Alzheimer’s pathologies now can be reliably quantified in vivo using regular blood tests.
from journals https://ift.tt/30OYZlk
from journals https://ift.tt/30OYZlk
Comments
Post a Comment